XV Congresso Nazionale Sihta

October 25-27, 2022 | Rome, Italy

We are pleased to share that we will be joining as speakers and sponsors XV Congresso Nazionale Sihta, a key event for Italian Healthcare industry.

Our speeches:
Digital Health e Real World Evidence: Valutazione di un modello a supporto di processi decisionali in ambito HTA

English title:
Digital Health and Real World Evidence: Evaluation of the Decision-Making Model in HTA

Firenze G. Monterosso A, Romeo J.

Presented by:
Giovanni Firenze, Market Access and Pricing Director, Italy, Alira Health

Presentation time:
October 26, 16.30-17.30 CEST

Similitudini e differenze tra EUnetHTA e HTA nazionali: Aree di interesse per la futura metodologia HTA Europea

English title:
Similarities and Differences Between EUnetHTA and HTAs: Areas of Interest for the Future European HTA Methodology

Rabadi L, Couillerot AL, De la Paz I, Rodriguez N, Asmah A, Aguado M, Belamri M, Ottobrino V, Mangone M.

Presented by:
Monica Mangone, Global Market Access Senior Consultant, Alira Health

Presentation time:
October 26, 16.30-17.30 CEST

Published on:
September 30, 2022
Our Speakers:
Giovanni Firenze

Giovanni Firenze

Market Access and Pricing Director, Italy, Alira Health Giovanni has started his career in Eli Lilly in Germany and in the UK as a Manager of a Sales & Marketing European Project, moving thereafter to Bristol Myers Squibb in the USA and later in Italy covering European positions.

In 2002, he joined the management consulting arena working for Arthur D. Little International, IMS Health Consulting Group (UK), as a Director, Executive Insight (Switzerland), HBI and Vintura.

During his career, Giovanni carried out and led multiple projects in different Therapeutic Areas, such as Respiratory, Cardiology, Oncology, Hematology, GI, Rare Diseases and CNS for pharma and biotech companies. His consulting experience extends also to the molecules and digital health solutions.

Giovanni holds a MS degree in Engineering from the University of Genoa and an MBA from SDA Bocconi and University of Michigan – Stephen Ross Business School.
Monica Mangone

Monica Mangone

Global Market Access Senior Consultant, Alira Health Experienced Market Access professional with 15+ years of experience in Healthcare and Pharmaceutical Industries, Monica worked at Novartis, Amgen and AstraZeneca prior to joining Alira Health.

Monica also managed several Dossier of P&R negotiations with AIFA, executed robust cross-functional National International and regional market access plan to support launches of new products (oncology and rare disease included).

Monica holds a BSc in Science and MSc in Health Economics from University of Milan, is currently a member of the HBA Healthcare Businesswomen's Association, and has been an ICF certified coach since 2000.
Our Delegates:
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access and Pricing, Alira Health
Veronica Ottobrino

Veronica Ottobrino

Analyst, Global Market Access, Alira Health

Would you like to meet Alira Health at XV Congresso Nazionale Sihta? Contact us to set up a meeting.

Related news

Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
Publications February 15, 2024
FDA Approves GAMMAGARD LIQUID Based on Safety Data From an RWE Study
Food and Drug Administration (FDA) approves GAMMAGARD LIQUID based on safety data from a real-world evidence study.
Real-World Evidence (RWE) RWE Decision Alert
Publications February 9, 2024
UK HTA Recommends KANUMA in Pediatric Patients Based Partly on Comparative RWD
KANUMA underwent a recent appraisal by the UK's NICE for the treatment of Wolman disease in children aged two years and under.
Real-World Evidence (RWE) RWE Decision Alert
Publications February 1, 2024
French HTA Maintains Reimbursement of HyQvia in Adults and Extends Reimbursement to Children, Largely Driven by RWE
French HTA maintains reimbursement of HyQvia in adults and extends reimbursement to children, largely driven by RWE.
Real-World Evidence (RWE) RWE Decision Alert
Publications December 14, 2023
Germany Shifts from Next Generation Sequencing Panels to Whole Genome Sequencing Coverage
Germany takes next step in approach to genomic medicine. This article explores its impact on patients, IVD manufacturers, and RWE solution providers.
In-Vitro Diagnostic Regulation Real-World Evidence (RWE)
Blog December 5, 2023
Handling Uncertainty in Health-Economic Assessments: Experience from COVID-19 in France
This article explores how economic evaluations were used to appraise COVID-19 treatments in France to identify areas of improvement for future.
France HEOR Real-World Evidence (RWE)
Multimedia November 28, 2023
How to Accelerate Lupus Solutions with RWD
Explore lupus solutions and real-world treatment impacts through a discussion on patient aspects and the role of technology in streamlining research efficiency.
Lupus Patient Centricity Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.